Moneycontrol PRO
you are here: HomeNewsRanbaxylabs
results
Jump to
61 Results Found
  • Integration costs to continue into FY16: Sun Pharma Jun 01, 2015 01:19 PM IST

    Integration costs to continue into FY16: Sun Pharma

    Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

  • Sun will turn Ranbaxy profitable; stock fall brief: Angel Jun 01, 2015 01:04 PM IST

    Sun will turn Ranbaxy profitable; stock fall brief: Angel

    Sarabjit Kaur Nangra of Angel Broking is neutral on Cipla as of now because the price has run up ahead of fundamentals.

  • Ranbaxy effect playing on Sun Pharma's margins: Pros May 29, 2015 07:18 PM IST

    Ranbaxy effect playing on Sun Pharma's margins: Pros

    Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after consolidation she was looking at closer to 30 percent.

  • Sun Pharma Q4 profit seen up 9.7%, sales may rise 16%: Poll May 28, 2015 05:02 PM IST

    Sun Pharma Q4 profit seen up 9.7%, sales may rise 16%: Poll

    Drug major Sun Pharmaceutical Industries's fourth quarter consolidated profit is likely to increase 9.7 percent year-on-year to Rs 1,659.85 crore, according to a CNBC-TV18 poll. The numbers will be announced on May 29.

  • Sun Pharma maintains 13-15% FY15 topline guidance: CFO Feb 18, 2015 02:54 PM IST

    Sun Pharma maintains 13-15% FY15 topline guidance: CFO

    The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.

  • Operating performance may hurt Sun Pharma's Q3 profit: Poll Feb 13, 2015 02:46 PM IST

    Operating performance may hurt Sun Pharma's Q3 profit: Poll

    Sun Pharmaceutical Industries will announce its third quarter earnings on Saturday. According to a CNBC-TV18 poll, net profit of the drug maker may rise 7 percent year-on-year to Rs 1,638 crore during October-December quarter, impacted by lower operating performance.

  • Ranbaxy Q3 disappoints; US mkt, Diovan led to loss: Angel Jan 28, 2015 03:08 PM IST

    Ranbaxy Q3 disappoints; US mkt, Diovan led to loss: Angel

    Speaking to CNBC-TV18, Sarabjit Kaur Nangra of Angel Broking said on the bottomline, margins suffered due to forex loss. The drug maker reported a forex loss of Rs 132.6 crore versus gain of Rs 10.1 crore from a year ago period.

  • Ranbaxy Labs Q3 revenue may rise 12% to Rs 3236 cr: Poll Jan 28, 2015 11:15 AM IST

    Ranbaxy Labs Q3 revenue may rise 12% to Rs 3236 cr: Poll

    Ranbaxy Laboratories, which will soon become a part of Sun Pharma, will announce its third quarter (October-December) earnings today. Analysts expect the quarter to be a good one due to Diovan generic (is used to treat high blood pressure).

  • Merger with Ranbaxy might get delayed: Sun CFO Baldota Nov 14, 2014 11:59 AM IST

    Merger with Ranbaxy might get delayed: Sun CFO Baldota

    The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.

  • US core business continues to be a drag for Ranbaxy: CIMB Oct 29, 2014 09:05 AM IST

    US core business continues to be a drag for Ranbaxy: CIMB

    Prakash Agarwal, Equity Analyst, CIMB has a hold rating on Ranbaxy with target price of Rs 630/share.

  • Here's how experts read Ranbaxy's Q2FY15 earnings Oct 28, 2014 03:59 PM IST

    Here's how experts read Ranbaxy's Q2FY15 earnings

    Ranbaxy Laboratories has turned profitable in the second quarter of current financial year. The company reported consolidated net profit of Rs 478 crore during the quarter as against loss of Rs 454 crore in the year-ago period.

  • Brokerages wary about Ranbaxy sustaining its performance Feb 06, 2014 08:08 PM IST

    Brokerages wary about Ranbaxy sustaining its performance

    Brokerages wary about Ranbaxy sustaining its performance

  • Healthy sales, operational growth push Ranbaxy 6% up: Angel Feb 05, 2014 03:25 PM IST

    Healthy sales, operational growth push Ranbaxy 6% up: Angel

    Ranbaxy Laboratories, which has been struggling for drug production due to USFDA issues, reported a net loss of Rs 159 crore for the fourth quarter (October-December) as against loss of Rs 486.55 crore in same quarter last year.

  • Key takeaways from Ranbaxy earnings commentary Feb 05, 2014 02:27 PM IST

    Key takeaways from Ranbaxy earnings commentary

    In a conference call, the company, now owned by Japanese Daiichi Sankyo, said it was committed to resolving issues with the FDA, which has now banned imports from all four its plants in India.

  • Ranbaxy may post Q3 PAT at Rs 10 cr, guidance revision key Feb 05, 2014 10:18 AM IST

    Ranbaxy may post Q3 PAT at Rs 10 cr, guidance revision key

    Analysts are worried about the guidance (Rs 13,000-13,500 crore - with no first-to-file included) after the US Food and Drug Administration (USFDA) banned manufacturing and distributing active pharmaceutical ingredients from its Toansa facility. Toansa was the fourth plant that was banned by USFDA after Mohali, Dewas and Poanta.

  • Ranbaxy Q3 net may rise 83.5% at Rs 112cr: Motilal Oswal Feb 05, 2014 10:09 AM IST

    Ranbaxy Q3 net may rise 83.5% at Rs 112cr: Motilal Oswal

    Sales of Ranbaxy Laboratories are expected to increase by 2.8 percent Q-o-Q (up 15.7 percent Y-o-Y) to Rs 2879.1 crore, according to Motilal Oswal.

  • What you can expect from Ranbaxy in Oct-Dec quarter Feb 05, 2014 09:07 AM IST

    What you can expect from Ranbaxy in Oct-Dec quarter

    Ranbaxy Laboratories is expected to release its Q3 numbers today.

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi Jan 03, 2014 05:34 PM IST

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi Oct 30, 2013 03:27 PM IST

    Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi

    He is positive on Dr Reddy mainly because the company is going to benefit significantly in FY14 and FY15 from the new launches and at the same time the margins will also be higher. He does not expect any major surprise coming in Lupins' quarterly result.

  • Ranbaxy disappoints on lower OPM, net profit: Angel Broking Oct 29, 2013 08:27 PM IST

    Ranbaxy disappoints on lower OPM, net profit: Angel Broking

    Angel Broking's Sarabjit Kaur Nangra believes the Q2 earnings of Ranbaxy is lower than expectations as both the operating performance and the net profit of the company are disappointing

  • Ranbaxy Q2 PAT may dip 19% at Rs 166.3 cr: Motilal Oswal Oct 28, 2013 06:39 PM IST

    Ranbaxy Q2 PAT may dip 19% at Rs 166.3 cr: Motilal Oswal

    According to Motilal Oswal, Ranbaxy Laboratories to report a 27.8 percent growth quarter-on-quarter (down 19.1 percent Y-o-Y) in net profit at Rs 166.3 crore.

  • Ranbaxy likely to post Q3 loss at Rs 25.9 cr: P Lilladher Oct 28, 2013 06:33 PM IST

    Ranbaxy likely to post Q3 loss at Rs 25.9 cr: P Lilladher

    According to Prabhudas Lilladher, Ranbaxy Laboratories may report a 95.1 percent degrowth quarter-on-quarter (down 103.4 percent Y-o-Y) in net loss at Rs 25.9 crore.

  • Ranbaxy Labs Q1 net seen down 60.5% at Rs 150 cr: Emkay Aug 06, 2013 05:40 PM IST

    Ranbaxy Labs Q1 net seen down 60.5% at Rs 150 cr: Emkay

    Emkay Equity Advisory expects Ranbaxy Laboratories to report a 145.4 percent growth quarter-on-quarter (decline of 60.5 percent year-on-year) in net profit at Rs 150.1 crore.

  • Ranbaxy Labs Q1: MOST expects PAT to dip 39% at Rs 105.5 cr Aug 06, 2013 05:30 PM IST

    Ranbaxy Labs Q1: MOST expects PAT to dip 39% at Rs 105.5 cr

    Motilal Oswal expects Ranbaxy Laboratories to report a 16.7 percent growth quarter-on-quarter (decline of 38.8 percent year-on-year) in net profit at Rs 105.5 crore.

  • Ranbaxy Labs Q1 net may dip 127% at Rs 159 cr: P Lilladher Aug 06, 2013 05:24 PM IST

    Ranbaxy Labs Q1 net may dip 127% at Rs 159 cr: P Lilladher

    Prabhudas Lilladher expects Ranbaxy Laboratories to report a 26.1 percent growth quarter-on-quarter (decline of 127.1 percent year-on-year) in net profit at Rs 158.6 crore.

Sections
ISO 27001 - BSI Assurance Mark